KBI Biopharma is a leading contract development and manufacturing organization (CDMO) dedicated to accelerating the development and commercialization of biopharmaceuticals. With a proven track record of scientific expertise and technical innovation, KBI provides fully integrated services to support the development, manufacturing, and analytical needs of its clients.

KBI’s comprehensive offerings include cell line development, process development, analytical testing, and GMP manufacturing for a wide range of biologics, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Their state-of-the-art facilities and advanced technologies ensure the delivery of high-quality, scalable, and cost-effective solutions tailored to meet the unique requirements of each project.

With a customer-focused approach, KBI Biopharma partners with biopharmaceutical companies of all sizes, from emerging biotech firms to global pharmaceutical leaders. Their team of experienced scientists and engineers works collaboratively with clients to overcome complex challenges, ensuring the successful development and production of life-saving therapies.

KBI Biopharma’s mission is to enable the development of innovative medicines that improve patient lives. By combining scientific excellence, cutting-edge technology, and a commitment to quality, KBI continues to be a trusted partner in the biopharmaceutical industry.